The immune system and kidney disease: Basic concepts and clinical implications

1] Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Str. 25, 53105 Bonn, Germany. [2].
Nature Reviews Immunology (Impact Factor: 34.99). 09/2013; 13(10). DOI: 10.1038/nri3523
Source: PubMed


The kidneys are frequently targeted by pathogenic immune responses against renal autoantigens or by local manifestations of systemic autoimmunity. Recent studies in rodent models and humans have uncovered several underlying mechanisms that can be used to explain the previously enigmatic immunopathology of many kidney diseases. These mechanisms include kidney-specific damage-associated molecular patterns that cause sterile inflammation, the crosstalk between renal dendritic cells and T cells, the development of kidney-targeting autoantibodies and molecular mimicry with microbial pathogens. Conversely, kidney failure affects general immunity, causing intestinal barrier dysfunction, systemic inflammation and immunodeficiency that contribute to the morbidity and mortality of patients with kidney disease. In this Review, we summarize the recent findings regarding the interactions between the kidneys and the immune system.

Download full-text


Available from: Christian Kurts, Jun 12, 2015
  • Source
    • "UPEC can persist intracellularly, and cause relapsing infections (Martinez et al., 2000), which is associated with an increased risk for bladder cancer (Parker et al., 2004). Their ascension into the kidney causes pyelonephritis, which can progress to renal failure (Kurts et al., 2013; Svensson et al., 2011). The defense against UTI depends on neutrophils (Frendé us et al., 2000). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The phagocytes of the innate immune system, macrophages and neutrophils, contribute to antibacterial defense, but their functional specialization and cooperation is unclear. Here, we report that three distinct phagocyte subsets play highly coordinated roles in bacterial urinary tract infection. Ly6C(-) macrophages acted as tissue-resident sentinels that attracted circulating neutrophils and Ly6C(+) macrophages. Such Ly6C(+) macrophages played a previously undescribed helper role: once recruited to the site of infection, they produced the cytokine TNF, which caused Ly6C(-) macrophages to secrete CXCL2. This chemokine activated matrix metalloproteinase-9 in neutrophils, allowing their entry into the uroepithelium to combat the bacteria. In summary, the sentinel macrophages elicit the powerful antibacterial functions of neutrophils only after confirmation by the helper macrophages, reminiscent of the licensing role of helper T cells in antiviral adaptive immunity. These findings identify helper macrophages and TNF as critical regulators in innate immunity against bacterial infections in epithelia.
    Full-text · Article · Jan 2014 · Cell
  • [Show abstract] [Hide abstract]
    ABSTRACT: The concept of reversing chronic kidney disease (CKD) has been intensively researched over the past decade. Indeed, as the prevalence of end-stage renal disease is constantly on the rise, the lack of established antifibrotic therapies is a considerable unmet need in clinical practice. Now, the possibility of effective antifibrotic treatment has been established in experimental models of CKD and multiple antifibrotic compounds-in kidney disease, as well as in fibrotic diseases of the skin, liver and lung-are being assessed in clinical trials. These strategies target various components of the fibrotic pathway, from signalling molecules that include transforming growth factor-β, phosphatidylinositide 3-kinase and chemokines to microRNAs. Here, we discuss therapeutic concepts to inhibit or even reverse chronic kidney injury and review the leading candidate antifibrotic drugs to be introduced to clinical use.
    No preview · Article · Feb 2014 · Nature Reviews Nephrology
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim is to find predictors for a prolonged LOHS after MitraClip® implantation. Due to its less invasive nature, average length of hospital stay (LOHS) after the MitraClip® procedure is shorter compared to mitral valve surgery. However, some patients have a prolonged LOHS. Records of consecutive patients who underwent MitraClip® procedure were reviewed. A total of 41 consecutive patients with MitraClip® implantation (76 ± 9 years, 59% men) were included. Median hospital stay was 7 days. Hospitalization lasting longer than 7 days was considered prolonged. Procedural success was achieved in 88% of the cases. In-hospital death occurred in 4 of 41 patients (10%). Patients with a prolonged hospital stay (46%) had a higher EuroSCORE I (22.7% [IQR 10.3 - 28.3] vs. 6.7% [IQR 3.5 - 18.3], p=0.017), a higher STS mortality score (6.1%[(IQR 3.7 - 7.5] vs. 2.6% [IQR 1.4 - 4.8]; p= 0.043) and a higher STS long-length-of-stay score (18.9% [IQR 11.3 - 22.5] vs. 9.6% [IQR 6.2 - 16.1]; p= 0.039) as well as a lower estimated glomerular filtration rate (eGFR) (41 ml/min/1.73m(2) [IQR 19 - 52] vs. 56 ml/min/1.73m(2) [IQR 49 - 62]; p= 0.008) than those whose did not. In the multivariate model, lower eGFR was identified as predictor for a prolonged hospitalization. Lower pre-procedure eGFR is independently associated with a longer hospitalization. © 2014 Wiley Periodicals, Inc.
    No preview · Article · Feb 2014 · Catheterization and Cardiovascular Interventions
Show more